Pharmacy

Your Article Summary

See Latest Articles

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients With Acute Ischemic Stroke. Modified Randomized Exposure Controlled Trial (mRECT)
Stroke, 09/14/09

Teal P et al. – mRECT demonstrated the feasibility of conducting a rigorous trial using a short therapeutic window demanding clinical and radiographic criteria to optimize patient selection and a Point–of–Care test to achieve a targeted exposure to repinotan. The study failed to demonstrate a clinical benefit of repinotan. The development of repinotan in acute ischemic stroke was discontinued.

Today in Neuro/Psych pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Modafinil for multiple sclerosis fatigue: Does it work
Clinical Neurology and Neurosurgery, 12/18/09

Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry in six countries
Current Medical Research and Opinion, 12/18/09

Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders
Phytotherapy Research, 12/18/09

 See all of Neuro/Psych pharmacology